We are live on
!
Find out more
BCAM
Boston Common Asset Management Portfolio holdings
AUM
$1.69B
1-Year Est. Return
28.29%
This Fund
S&P 500
This Quarter
Est. Return
+6.44%
1 Year Est. Return
+28.29%
3 Year Est. Return
+54.94%
5 Year Est. Return
+54.02%
10 Year Est. Return
+260.31%
AUM
$3.57B
AUM Growth
+$273M
(+8.3%)
Cap. Flow
-$19.8M
Cap. Flow
% of AUM
-0.56%
Top 10 Holdings %
Top 10 Hldgs %
15.41%
Holding
325
New
35
Increased
82
Reduced
162
Closed
28
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Quest Diagnostics
DGX
|
+$12.9M |
| 2 |
Salesforce
CRM
|
+$9.6M |
| 3 |
TSMC
TSM
|
+$9.22M |
| 4 |
KLA
KLAC
|
+$7.93M |
| 5 |
Eli Lilly
LLY
|
+$6.58M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$17.3M |
| 2 |
HOLX
Hologic
HOLX
|
+$16.8M |
| 3 |
Micron Technology
MU
|
+$10M |
| 4 |
Zimmer Biomet
ZBH
|
+$6.83M |
| 5 |
Ball Corp
BALL
|
+$6.55M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 13.67% |
| 2 | Financials | 8.72% |
| 3 | Healthcare | 5.78% |
| 4 | Communication Services | 4.95% |
| 5 | Industrials | 4.85% |
Similar funds
GAM
FACM
TCBWMS
PP
ISS
BA
RMC
BCM
Boston Common Asset Management's Q2 2025 Portfolio in Review
As of Q2 2025, Boston Common Asset Management held 325 positions worth $3.57B, up 8.3% from $3.29B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Boston Common Asset Management's Q2 2025 filing shows 35 new, 82 increased, 162 reduced and 28 closed positions. Its largest new stake was Quest Diagnostics: 74,250 shares worth $13.3M. The largest sale was Regeneron Pharmaceuticals, an estimated $17.3M.
By sector, the portfolio is most concentrated in Technology at 14% of assets, up from 12% a quarter earlier, followed by Financials and Healthcare.
- Boston Common Asset Management's largest Q2 2025 buy was Quest Diagnostics: 74,250 shares worth $13.3M.
- Boston Common Asset Management added most to Salesforce in Q2 2025, an estimated $9.6M increase.
- Boston Common Asset Management's biggest Q2 2025 reduction was Micron Technology, cutting an estimated $10M.
- Boston Common Asset Management fully exited Regeneron Pharmaceuticals in Q2 2025, selling an estimated $17.3M.
- Boston Common Asset Management's ten largest holdings make up 15% of its $3.57B portfolio in Q2 2025.
- Boston Common Asset Management opened 35 new positions and closed 28 in Q2 2025.
- Boston Common Asset Management's portfolio value rose 8.3% quarter-over-quarter to $3.57B.
Based on Boston Common Asset Management's 13F filing for Q2 2025, filed 22 Jul 2025.